Pharmacology of a new low molecular weight dermatan sulphate (Desmin) in healthy volunteers: repeated daily intramuscular administration of 400 mg for a week

Thromb Res. 1996 Jul 1;83(1):103-9. doi: 10.1016/0049-3848(96)00108-9.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Blood Coagulation Tests
  • Dermatan Sulfate / administration & dosage
  • Dermatan Sulfate / adverse effects
  • Dermatan Sulfate / pharmacology*
  • Factor Xa Inhibitors
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / pharmacology*
  • Humans
  • Injections, Intramuscular
  • Male
  • Molecular Weight
  • Partial Thromboplastin Time
  • Safety
  • Thrombin Time

Substances

  • Factor Xa Inhibitors
  • Fibrinolytic Agents
  • Dermatan Sulfate